SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

To advance the adoption of precision oncology, it is crucial to have access to large-scale data from a wide range of modalities (such as imaging, genomics, pathology and clinical notes), and diverse set of patient profiles. Currently, no single institution globally collects the necessary volume and diversity of information to propel the healthcare field forward. SOPHiA GENETICS has launched SOPHiA UNITY to answer that need and meet the demand for high-quality, diverse data at scale, aiming to drive a new era of precision oncology research.

The collective intelligence network will advance research initiatives using SOPHiA CarePath, the multimodal module on the SOPHiA DDM Platform, to aggregate and analyze complex real-world data. This data will be harmonized and curated using SOPHiA GENETICS’ advanced AI-based technology and proprietary algorithms. Through SOPHiA GENETICS’ unique platform and CarePath offering, SOPHiA UNITY members will have access to meaningful, data-driven insights that will support decision-making and expedite oncology research.

“At SOPHiA GENETICS, we have mastered the challenge of harmonizing and connecting genomic data and have the capabilities to do the same with other modalities through our CarePath module,” said Jurgi Camblong, PhD., Co-founder and CEO of SOPHiA GENETICS. “SOPHiA UNITY will usher in the next era of precision medicine innovation by bringing together best-in-class institutions that are committed to the advancement of oncology research and the use of data-driven medicine. We are extremely optimistic about the insights this collective intelligence network will generate to further our shared goal.”

SOPHiA GENETICS announced that the first member to join SOPHiA UNITY is Memorial Sloan Kettering Cancer Center, a top cancer treatment and research institution and world leader in patient care, research, and educational programs. Additional members will be announced in the coming months.

“I am looking forward to participating in the new data-driven consortium and partnering with other institutions to draw deeper insights from our collective data,” said Mrinal Gounder, M.D., Sarcoma Oncologist & Early Drug Development Specialist and Physician Ambassador to India and Asia, Memorial Sloan Kettering Cancer Center.

Leading academic cancer centers who are looking to connect with like-minded researchers globally are eligible to join the SOPHiA UNITY collective intelligence network and gather insights that can be implemented locally. For more information, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post SOPHiA GENETICS Launches Global Consortium, to Accelerate Healthcare Industry first appeared on AI-Tech Park.

This real-world analysis indicates many mCRPC patients with homologous recombination repair gene mutation (HRRm) are receiving several lines of therapy prior to olaparib, even when novel hormonal agents (NHA) are used prior to mCRPC. HRRm+ patients with confirmed mCRPC diagnosis, age ≥21 years, treated with olaparib monotherapy (post May 19, 2020) and prior to abiraterone or enzalutamide were abstracted from electronic medical records in the ConcertAI Oncology Dataset with PC diagnosis between 1990 and 2023. Frequency of patients who progressed from metastatic hormone-sensitive PC (mHSPC) and from non-metastatic CRPC (nmCRPC) to mCRPC and treatment patterns prior to mCRPC were summarized.

Jeff Elton, PhD, CEO of ConcertAI stressed, “This study underscores the potential of real-world data to support specific treatment decisions and improved patient outcomes. By analyzing our vast dataset of de-identified patient records, we were able to provide compelling evidence that earlier treatment with olaparib can significantly extend the duration of therapy and overall survival for patients with metastatic castration-resistant prostate cancer. This reinforces our core mission of transforming data housed in electronic health records into actionable insights that directly benefit patient care.”

This study will be presented at a poster session at the ASCO Annual Meeting 2024 on Sunday, June 2, between 9:00 am and 12:00 pm. Please visit poster #460 to learn more during that time. Alternatively, please visit the ConcertAI booth number 12045 at any time during exhibit hall hours.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post ASCO 2024 study uses ConcertAI Oncology Dataset to find earlier treatment first appeared on AI-Tech Park.

The American Cancer Society estimates that of the 2 million new cancer cases in the U.S. in 2023, about half could be eligible for immunotherapy treatment. While this treatment stimulates the patient’s immune system to fight cancer, it can potentially trigger an overactive immune response, leading to irAEs.

Managing irAEs is challenging due to the unique immune responses and variability in the reaction to immunotherapy. The intensified immune response that fights cancer cells can inadvertently harm normal tissues. Effective communication is crucial to educate patients about possible side effects, readiness for assistance, and timely medical intervention. Mild irAEs can often be managed symptomatically with topical treatments, while severe cases may require discontinuing immunotherapy and administering immune-suppressing medications.

To address the complexities of managing irAEs, Medigator offers real-time assistance to physicians. This tool manages the risk of irAEs and is seamlessly integrated into the Computerized Physician Order Entry system.

“By harnessing the power of big data analytics, Medigator analyzes real-world patient experiences with irAEs, physicians’ management strategies, and patient responses to treatment based on a dataset of 197,921 claim-based prescriptions. Using these analytical parameters, Medigator goes a step further by predicting the risk levels of different irAEs in individual patients. It provides personalized medication options by considering factors such as patient age, gender, race, chronic medical conditions, and genetic history, empowering physicians to enhance their risk management strategies in the care plan,” explained Jim Long, CEO of AESOP Technology.

“Medigator is an immunotherapy medication navigator designed for physicians. It aims to minimize interruptions in immunotherapy, preserve valuable treatment time and resources, and alleviate the treatment burden,” said Jim Long.

“The origin of the partnership between AESOP Technology and AstraZeneca Taiwan traces back to 2019 at an international biomedical accelerator co-hosted by AstraZeneca A.Catalyst Network and the National Biotechnology Research Park in Taiwan, which is dedicated to exploring new possibilities to change patients’ lives. Medigator has set a promising example demonstrating patient-centric innovation by advancing shared decision-making in precision medicine,” said Ben Chen, Medical Director, AstraZeneca Taiwan.

The research findings of Medigator, which were recently presented at the annual meeting of the American Society of Clinical Oncology, received notable attention. AESOP Technology continues its unwavering commitment to delivering physicians with precise and personalized solutions for irAEs as immunotherapy advances. Its ultimate goal is to enhance immunotherapy treatment outcomes and improve patients’ overall quality of life.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

The post Aesop Technology Announces Collaboration with Astrazeneca Taiwan first appeared on AI-Tech Park.

The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.

Precision medicine is a concept that collectively integrates the outcomes and the endeavours of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, the public investment led to the evolution of the personalization of disease-based therapies.

The precision medicine concept is a systematic process aiming to achieve victory over a disease such as cancer. Cancer is the major focus of various precision medicine initiatives, and precision oncology centers around matching the most accurate and precise treatment to each cancer patient on the basis of an individual’s matching genetic profile that could ultimately let them benefit from the treatment offered.

Factors fuelling the growth of the market include increasing incidence of cancer globally, decreasing trial and error-based drug prescription through pharmacogenomics, increasing usage of predictive biomarkers for cancer diagnostics, and rapid technological advancements related to oncology precision medicine.

Within the research report, the market has been segmented based on ecosystem, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the prevalence of cancer globally has created a buzz among companies to invest in oncology precision medicine.

Based on region, North America holds the largest share, owing to rising cancer prevalence and improvised regulatory policies pertaining to precision oncology in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.

Market Segmentation

• Ecosystem – Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics
• Application – Solid Tumor and Hematological Malignancies

Regional Segmentation

• North America: U.S., Canada
• Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe
• Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Increasing Incidence of Cancer Globally
• Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
• Increasing Usage of Predictive Biomarker for Cancer Diagnostics
• Rapid Technological Advancements related to Oncology Precision Medicine
• Decreasing Cost and Increase in the Output of Genomic Sequencing

Market Challenges

• Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries
• Inadequate Reimbursement Scenario for Precision Medicine
• Lack of Expertise, Education, and Awareness for Precision Medicine Implementation

Market Opportunities

• Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods
• Expansion into the Emerging Markets
• Rising Number of Initiatives for Precision Oncology Research

Key Questions Answered in the Report

• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the major market drivers, restraints, and opportunities in the global oncology precision medicine market?
• What are the underlying structures resulting in the emerging trends within the global oncology precision medicine market?
• How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for oncology precision medicine?
• Who are the leading players with significant offerings to the global oncology precision medicine market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which ecosystem in the oncology precision medicine type has the most promising growth?
• What are the major applications employed in the global oncology precision medicine market? Which is the dominating application?
• Who are the key manufacturers in the global oncology precision medicine market, and what are their contributions? Also, what is the growth potential of each major oncology precision medicine manufacturer?
• What is the scope of the global oncology precision medicine market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which oncology precision medicine technology and end user dominate these regions?
• What are the emerging trends in the global oncology precision medicine market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the oncology precision medicine regime?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the regulatory procedures that are required to unify the approval process for the emerging oncology precision medicine market? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing oncology precision medicine adoption in regular healthcare routines? How are these gaps being tackled?

Key Topics Covered:

1 Markets
1.1 Industry Outlook
1.2 Evolution of Precision Medicine for Cancer Management and Treatment
1.3 Applications of Precision Medicine in Oncology
1.4 Impact of COVID-19 Pandemic on Global Oncology Precision Medicine Market
1.4.1 Disruption of Oncology Precision Medicine Due to COVID-19
1.4.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies
1.4.3 Interruption in Research and Clinical Development and Commercial Operation
1.4.3.1 Research and Clinical Development
1.4.4 Commercial Operation and Access
1.4.5 Navigating Crisis Recovery and Looking to the Future
1.5 Market Dynamics
1.5.1 Impact Analysis
1.5.2 Market Drivers
1.5.2.1 Increasing Incidence of Cancer Globally
1.5.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
1.5.2.3 Increasing Usage of Predictive Biomarker for Cancer Diagnostics
1.5.2.4 Rapid Technological Advancements related to Oncology Precision Medicine
1.5.2.5 Decreasing Cost and Increase in the Output of Genomic Sequencing
1.5.3 Restraints
1.5.3.1 Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries
1.5.3.2 Inadequate Reimbursement Scenario for Precision Medicine
1.5.3.3 Barriers in the Advancement of Precision Medicine
1.5.3.3.1 Regulatory Barriers
1.5.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
1.6 Market Opportunities
1.6.1 Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods
1.6.2 Expansion into the Emerging Markets
1.6.3 Rising Number of Initiatives for Precision Oncology Research
1.7 Competitive Landscape
1.7.1 Acquisitions
1.7.2 Synergistic Activities
1.7.3 Product Launches, Approvals, and Upgradations
1.7.4 Business Expansion
1.7.5 Market Share Analysis
1.7.6 Growth Share Analysis
1.7.6.1 Growth Share Analysis (by Application)
1.7.6.2 Growth Share Analysis (by Ecosystem)
1.8 Industry Insights
1.9 Legal Requirements and Framework by MHLW
1.10 Legal Requirement and Framework by NMPA
1.11 Patent Analysis

2 Global Oncology Precision Medicine Market, by Ecosystem, $ Million, 2020-2031
2.1 Overview
2.1.1 Precision Therapeutics
2.1.1.1 Clinical Trials
2.1.1.2 Biomarker Testing
2.1.1.3 Drug Discovery and Research
2.1.1.4 Gene Therapy
2.1.1.5 Cell Therapy
2.1.2 Applied Sciences
2.1.2.1 Genomics
2.1.2.1.1 Polymerase Chain Reaction (PCR)
2.1.2.1.2 Precision Medicine Next-Generation Sequencing
2.1.2.1.3 Genome Editing
2.1.2.1.4 Other Technologies
2.1.2.2 Pharmacogenomics
2.1.2.3 Other Applied Sciences
2.1.3 Digital Health and Information Technology
2.1.3.1 Clinical Decision Support System (CDSS)
2.1.3.2 Big Data Analytics
2.1.3.3 IT Infrastructure
2.1.3.4 Genomics Informatics
2.1.3.5 In-Silico Informatics
2.1.3.6 Mobile Health
2.1.4 Precision Diagnostics
2.1.4.1 Molecular Diagnostics (MDx)
2.1.4.2 Medical Imaging

3 Global Oncology Precision Medicine Market, by Application, $ Million, 2020-2031
3.1 Overview
3.1.1 Solid Tumor
3.1.1.1 Breast Cancer
3.1.1.2 Lung Cancer
3.1.1.3 Colorectal Cancer
3.1.1.4 Prostate Cancer
3.1.1.5 Cervical Cancer
3.1.1.6 Other Cancer
3.1.2 Hematological Malignancies (HMs)
3.1.2.1 Leukemia
3.1.2.2 Lymphoma
3.1.2.3 Myeloma or Multiple Myeloma (MM)
3.1.2.4 Other Hematological Malignancies

4 Global Oncology Precision Medicine Market, by Regions, $ Million, 2020-2031

5 Markets – Competitive Benchmarking & Company Profiles
5.1 Overview
5.2 Agilent Technologies, Inc.
5.2.1 Company Overview
5.2.2 Role of Agilent Technologies, Inc. in the Global Oncology Precision Medicine Market
5.2.3 Key Competitors of the Company
5.2.4 Financials
5.2.5 Key Insights About Financial of the Company
5.2.6 Corporate Strategies
5.2.6.1 Mergers and Acquisitions
5.2.6.2 Synergistic Activities
5.2.6.3 Business Expansion and Funding
5.2.6.4 Product Launches and Upgradation
5.2.7 SWOT Analysis
5.3 Bio-Rad Laboratories, Inc.
5.4 Illumina, Inc.
5.5 Pacific Biosciences of California, Inc.
5.6 PerkinElmer Inc.
5.7 QIAGEN
5.8 Thermo Fisher Scientific Inc.
5.9 BGI Group
5.1 ASURAGEN, INC.
5.11 Almac Group Ltd.
5.12 MDxHealth
5.13 Abbott Laboratories
5.14 F. Hoffmann-La Roche Ltd
5.15 Gilead Sciences, Inc.
5.16 Myriad Genetics, Inc
5.17 OPKO Health, Inc.
5.18 Quest Diagnostics Incorporated
5.19 Novartis AG
5.2 Emerging Companies

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

The post Insights on the Oncology Precision Medicine Global Market to 2031 first appeared on AI-Tech Park.

With new studies emerging showing that microdosing psychedelics has a clear association with fewer symptoms of depression, anxiety, and stress, it’s no wonder there is such a desire to see Ei.Ventures’ Psilly and other psychedelic medicines hit the mainstream.

And as of last week Ei.Ventures announced some exciting news regarding its Go Public pathway: the company signed an LOI with Mycotopia (TPIA) to explore a merger and the formation of PSLY.COM, a $360 million transaction, and will apply to list shares on NASDAQ. More info about the potential merger and anticipated NASDAQ listing is available here. Ei.Ventures CEO David Nikzad notes, “This is a very exciting deal that provides more certainty in a ‘Go Public’ path forward and disrupts the typical investment-banker run going-public model which is often full of bumps and headwinds. Ei.Ventures anticipates closing on the merger in March 2022, assuming we reach a definitive agreement.”

Part of Ei.Ventures’ business strategy has been to develop revenue producing products and partnerships while the novel psychedelic medicines move down the clinical pathway and into legal jurisdictions. On that front the company has been working on three key partnerships over the past few months.

The first joint venture partnership is with The3RDBevCo out of New York. The3RDBevCo is focused on creating first to market functional beverages into the $110 billion global functional drink market. The3RDBevCo will produce the Psilli line of functional mushroom drinks. Psilli will come in five unique blends that target energy, immune support, sleep, cognition, and mood. Interested beverage and mushroom fans can register to win a lifetime supply on launch in late Q1 of 2022 and learn more about Psilli here.

Ei.Ventures also made progress on the clinical development front, with an engagement with Tioga Labs, a premier transdermal research and development company with US offices in San Diego, a noted biotech hub. Tioga has secured the required DEA credentials to handle psychedelic drugs, and has acquired the raw materials to begin development and testing of a transdermal delivery system. Forbes covered the engagement here.

In conjunction with the development of this novel transdermal formulation, Ei.Ventures has also signed a non-binding LOI with RYAH, a connected device, big data, and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. RYAH has developed a smart patch technology that would further enhance the transdermal delivery system.

The proposed collaboration is expected to:

• Assess the compatibility of the RYAH Smart Patch delivery and monitoring device, software, and data platform with Ei.Ventures’ proprietary psychedelic formulations
• Further Ei.Ventures’ research and development strategy, accelerating use testing on controlled delivery and monitoring of psychoactive compounds for mental wellness treatments
• Position the companies toward a commercial licensing arrangement to deliver psychedelic therapies, in anticipation of governmentally approved treatment options for mental healthcare

There is more info about the LOI here.

In addition to these, Ei.Ventures is working on finalizing an additional partnership with a biotech company focused on developing novel bio synthetic psychedelic materials. This would allow rapid production of botanical psilocin for the current clinical development at an incredibly low cost.

It would also allow pursuit of additional novel patents and IP within the space at a rapid pace. As such Fox Rothschild has been engaged as counsel for further IP development and filings.

The company anticipates that three other very major initiatives will be announced soon.

Ei.Ventures CEO David Nikzad concludes, “As 2021 comes to a close we would like to wish all in the psychedelic, startup, and investment communities, along with our new friends in the South Florida business community, who have been so incredibly welcoming, a wonderful holiday season and a fantastic new year in 2022.”

You can find the Offering Circular for Ei.Ventures’ Regulation A offering here https://www.sec.gov/Archives/edgar/data/1823182/000110465921096304/tm2123436d1_253g2.htm. For more information on Ei.Ventures, please go to https://invest.ei.ventures/. For media needs, please contact Susan von Seggern at susan@ei.ventures or 213-840-0077.

Forward Looking Statements: Certain information set forth in this presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company in connection therewith, contains “forward-looking statements” and “forward-looking information” within the meaning of applicable United States securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements related to activities, events or developments that Ei.Ventures expects or anticipates will or may occur in the future, statements related to the Company’s business strategy objectives and goals, and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections ,assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, ‘believe”, expect”, “intend”, “potential”, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

The post Ei.Ventures Closes Out an Exciting 2021 first appeared on AI-Tech Park.

The partnership will benefit life insurance customers during two key stages of the application process: pre-submission by leveraging ForMotiv’s proprietary behavioral intelligence platform to identify fraudulent, misrepresented, or malicious behaviors by users, and post-submission through Health Gorilla’s aggregation of complete medical records for risk assessment and underwriting purposes.

Health Gorilla, the largest aggregator of health data in the United States, securely provides life insurance underwriters with HIPAA-compliant, permission-based access to streamlined medical data through its FHIR-based clinical data APIs. Through this data access, insurers can better make informed decisions while assessing client risk.

ForMotiv is a leading behavioral intelligence provider working with Fortune 500 banks, financial institutions, and insurance carriers globally. The ForMotiv solution provides real-time predictive intelligence on customer intent as users engage with applications and forms, without needing any Personal Identifiable Information (PII). By analyzing hundreds of unique behavioral data points, or “digital body language,” while users fill out applications, ForMotiv can accurately predict end-user intent such as genuine or fraudulent users and transmit that intent scoring, in real-time, back to carriers during the workflow.

“We are excited to partner with ForMotiv as we expand our product offering for life insurance customers,” said Stacy Gill, Vice President of Life Insurance at Health Gorilla. “This is a giant step forward and we are confident that this partnership will provide a more comprehensive solution to life insurance underwriters and risk-assessment evaluators.”

“Health Gorilla’s dataset is the perfect complement for ForMotiv as we continue delivering underwriting value to life insurance carriers, said Woody Klemmer, Head of Growth at ForMotiv. “Combining our behavioral dataset and predictive intent intelligence with Health Gorilla’s leading healthcare dataset will, together, help carriers understand user intent and improve underwriting accuracy.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

The post Health Gorilla and ForMotiv Announce Strategic Partnership first appeared on AI-Tech Park.

As the communities’ trusted health system, Mount Nittany Health consists of Mount Nittany Medical Center, a 260-bed acute care, emergency and surgical facility, and Mount Nittany Physician Group, the largest medical group in the area with a staff of more than 170 providers, offering primary and specialty care services through a growing number of locations in central Pennsylvania.

Mount Nittany’s comprehensive population health solution will include Health Catalyst’s Data Operating System (DOS) platform, Leading Wisely, Population Builder, Able Health, and Value Optimizer, a newly launched population health solution that quickly identifies highly valuable opportunities for value-based care (VBC) performance improvement.

“We are excited to work with Mount Nittany Health to help the organization take meaningful steps forward on their path to achieving the promise of population health,” said Dan Burton, CEO of Health Catalyst. “Together, we will identify gaps in patient care, empower care teams to optimize treatment, and deliver massive, measurable, data-informed population health improvements.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

The post Mount Nittany Health Selects Health Catalyst first appeared on AI-Tech Park.

Intelligent Medical Objects (IMO), a healthcare data enablement company and market leader in medical terminology services, will be at the Healthcare Information and Management Systems Society (HIMSS21) meeting to showcase its diverse solutions that improve the quality of healthcare data.

“The COVID pandemic put an exclamation point on where we need improvements in healthcare,” said Ann Barnes, CEO, IMO. “Our team at IMO has worked tirelessly through the last year to understand the needs of our customers across the healthcare spectrum. We are proud of the role we have in optimizing healthcare delivery by improving data quality and are excited to showcase our solutions at HIMSS.”

In the last year, IMO has focused on innovative new offerings and building strategic partnerships across the health IT industry:

• Improving data quality – IMO Precision Normalize was developed tostandardize the enormous amounts of disparate clinical patient data in healthcare creating more complete, consistent, and accurate data to support direct care and fuel reliable insights. This technology is enriching data quality for organizations like CORHIO. With the Multiple Myeloma Research Foundation, IMO’s technology is enhancing the utility of the MMRF’s data for patient identification for clinical trials, cohort selection for health outcomes research, and the ability to provide analytic precision to the MMRF’s real-world data sources.
• Enhancing access to genomic data – Understanding genomic data is an essential step on the path to precision medicine. However, the integration and use of this data in clinical workflows has long been challenging. IMO’s technology is helping MEDITECH®normalize data to support the interoperability and utility of genomic data to enable better patient care.
• New offering for Cerner® users – IMO recently launched a new offering aimed at improving clinical documentation and problem list management for those using the Cerner® Millennium electronic health record. The IMO Core cSmart app – now available in the Cerner® code App Gallery – helps providers document with specificity, makes problem lists more meaningful, and helps to improve the capture of hierarchical condition categories (HCCs).
• Addressing scheduling inefficiencies – Operating room (OR) efficiency has been a critical issue throughout the pandemic.IMO Core Periop brings together the unparalleled perioperative expertise of AORN Syntegrity®with IMO’s industry-leading procedure terminology to help optimize preference cards, reduce denied claims, and improve OR and surgery center performance.
• Supporting critical code updates – IMO responded swiftly to the COVID-19 pandemic with critical coding updates to support electronic health record (EHR) workflows which were critical to the healthcare industry as providers were overwhelmed with patients and workload. Since the beginning of 2020, IMO has created 600,000 unique updates across its clinical terminologies. IMO’s teams review 1 million terms per year, with 400,000 updates made in 2020 alone to support standardized coding, reporting, and interoperability needs. IMO maps 2.9 million terms to all major coding systems including ICD-10-CM, CPT®, SNOMED CT®, and LOINC®.

If you would like to meet at HIMSS to learn more about IMO’s solutions, visit booth #2821.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

The post Healthcare Data Co. Intelligent Medical Objects to Showcase Expansion first appeared on AI-Tech Park.

DataDx®, business intelligence for independent medical and dental practices, today announced a partnership with Appy Health, a physician-focused and patient-centered app that works directly with insurance companies to track plan status and benefits; and provides doctors a portal with access to more accurate patient information and automation across all of their referring providers. Physicians and dentists who use Appy Health can now utilize DataDx analytics on top of that solution, which allows practitioners to strategically act and swiftly respond to market conditions leveraging their patient-level and payer data inexpensively and efficiently.

DataDx® is an advanced analytics platform that helps practitioners arrive at the true cost per unit of care. Private medical and dental practices are equipped to efficiently look at and analyze all expenses against revenue regardless of the data source. The data can then be acted on strategically to lower costs and ultimately achieve long-term and sustainable business results while continuing to offer top healthcare services. This is possible through a set of consolidated and meaningful financial reports. Other industry solutions fall short in that they do not provide a comprehensive view of costs.

“The partnership with Appy Health extends the reach and capabilities of DataDx,” says Kate Othus, DataDx founder and CEO. “Appy is a patient-facing application that will help our ability to connect with practice management and EMR systems, which to date are charging excessive integration fees which are punitive to private practice. This also provides an opportunity to dive further into value-based care reporting and predictive modeling initiatives.”

Private practices that are currently customers of Appy Heath also benefit from this partnership. They all receive an introductory version of DataDx, which they can upgrade to include accounting features at a discount.

“This partnership between Appy Health and DataDx drives better outcomes for physicians and dentists – and ultimately patients,” said Bill Grimes, founder and CEO, Appy Health. “Appy Health is the portal into Electronic Data Interchange and DataDx allows physicians to drive better analytics out of the stack as we track better patient data, together, across providers.”

Appy Health and DataDx will cross-sell the integrated solution.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

The post DataDx Partners with Appy Health to Integrate Healthcare Cost Data first appeared on AI-Tech Park.

Flatiron Health real-world data (RWD) supported the U.S. Food and Drug Administration (FDA)’s recent approval of a new dosing regimen for ERBITUX^® (Eli Lilly and Company’s cetuximab) that can have a direct positive impact on the lives of patients with metastatic colorectal cancer (CRC) or squamous cell carcinoma of the head and neck (SCCHN).

The FDA approved a supplemental biologics license application (sBLA) for ERBITUX which provides a new, biweekly dosing regimen for the medicine’s indicated use in patients with K-Ras wild-type, EGFR-expressing metastatic CRC or SCCHN, when used as a single agent or in combination with chemotherapy.

This alternate dosing regimen to the previously approved weekly dosing regimen allows ERBITUX infusions to be scheduled alongside other biweekly treatments, significantly reducing the frequency of patient visits to an infusion center.

“Time is a precious commodity for patients with advanced cancer – every moment that is not spent traveling to and from or in the clinic are moments spent living life,” said Michael Vasconcelles, MD, Chief Medical Officer at Flatiron Health. “We are proud that Flatiron RWD brings the evidence we gather from patients’ real-life experiences to bear directly on improvements to their care.”

“This dosing change approval allows physicians to provide our patients with the same efficacious treatments in less frequent clinic visits,” says Lee Schwartzberg, MD, Chief Medical Officer at OneOncology, a longtime Flatiron community oncology partner. “It is encouraging to see the innovative use of real-world data and regulatory pathways that made this label change a reality.”

The approval decision marked a foundational proofpoint for the successful use of RWD to fill evidence gaps in the post-approval setting for regulatory decision-making. Efficacy results from overall survival analyses using Flatiron RWD in patients with metastatic CRC, who received either the weekly or biweekly ERBITUX dosing regimens, supported the results of the population pharmacokinetic modeling analyses in the sBLA. The application was also supported by pooled analyses of overall response rates, progression-free survival, and overall survival (OS) from published literature in patients with CRC and SCCHN.

“We are proud that our long-standing partnership with Flatiron Health is helping to advance the adoption of real-world evidence to support regulatory decision-making,” said Christian Nguyen, Pharm.D., vice president of global patient outcomes and real-world evidence, Lilly Oncology. “Being able to fill key evidence gaps through the rigorous analysis of high-quality real-world data will help us all to more quickly bring potential new treatment options for approved medicines to patients.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

The post Flatiron Health Real-World Data Support FDA Approval first appeared on AI-Tech Park.